Abivax to Begin Testing Experimental Colitis Drug for Covid-19
This article is for subscribers only.
French biotech Abivax SA joined the race to find a treatment for the new coronavirus, saying its leading experimental medicine will be tested on about 1,000 high-risk Covid-19 patients in coming months.
The drug, under development to treat ulcerative colitis and rheumatoid arthritis, blocked the new coronavirus’s ability to replicate in lab experiments, Paris-based Abivax said in an emailed statement. Research also indicates the medicine, called ABX464, can quell excess inflammation -- a feature of severe Covid-19 cases -- and promote tissue healing, according to Abivax.